Low-dose taxanes induce γδ-T cell reprogramming and ANXA6/PPP2R1A release to synergistically treat triple-negative breast cancer
Taxanes play pivotal roles across therapeutic stages of triple-negative breast cancer (TNBC), yet their efficacy is substantially limited by drug resistance and systemic toxicity. Immunotherapy has been found to enhance the efficacy of chemotherapy. Here, we investigated the synergistic antitumor activity between tax...